文献速递生殖医学

新鲜与冷冻保存卵巢组织移植用于保留生殖和内分泌功能:系统综述与个体患者数据荟萃分析

Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis.
PubMed 文献 · Hum Reprod Update · 2022-01-01

该系统综述与个体患者数据荟萃分析纳入87项研究共735名女性,其中20项研究(568名女性)报告≥5例卵巢移植并纳入荟萃分析。冷冻卵巢组织移植后妊娠率37%(95%CI:32-43%)、活产率28%(95%CI:24-34%)、流产率37%(95%CI:30-46%),移植后雌二醇升高、FSH降低,卵巢组织冷冻保存与移植可恢复生殖和内分泌功能。

要点

  • 冷冻卵巢组织移植后汇总妊娠率37%(95%CI:32-43%)、活产率28%(95%CI:24-34%)、流产率37%(95%CI:30-46%)。
  • 移植前雌二醇均值101.6 pmol/l升至移植后522.4 pmol/l,FSH均值66.4 IU/l降至14.1 IU/l。
  • FSH恢复至<25 IU/l的中位时间19周,移植物功能中位持续时间2.5年。

核心结论

  • 卵巢组织冷冻保存与移植可恢复女性的生殖和内分泌功能。
  • 需要更大样本、特征明确人群的进一步研究来确定最佳获取、冷冻保存和移植流程。

研究设计与样本

  • 系统综述与个体患者数据荟萃分析,方案注册于PROSPERO(CRD42018115233)。
  • 检索MEDLINE、EMBASE、CINAHL和Cochrane对照试验中心注册库,从建库至2020年10月。
  • 纳入87项研究共735名女性,其中20项研究(568名女性)报告≥5例卵巢移植并纳入荟萃分析。
  • 采用逆方差加权固定效应模型计算汇总估计值。

主要发现

  • 冷冻卵巢组织移植后汇总妊娠率为37%(95%CI:32-43%)。
  • 冷冻卵巢组织移植后汇总活产率为28%(95%CI:24-34%)。
  • 冷冻卵巢组织移植后汇总流产率为37%(95%CI:30-46%)。
  • 移植前雌二醇汇总均值为101.6 pmol/l(95%CI:47.9-155.3),移植后升高至522.4 pmol/l(95%CI:315.4-729;均数差228.24;95%CI:180.5-276)。
  • 移植前FSH汇总均值为66.4 IU/l(95%CI:52.8-84),移植后降低至14.1 IU/l(95%CI:10.9-17.3;均数差61.8;95%CI:57-66.6)。

临床怎么用

  • 卵巢组织冷冻保存与移植可能不仅有效恢复生育力,还可恢复生殖内分泌功能。
  • 尽管该技术最初作为生育力保存选项开发,但作者认为其可能有用于内分泌功能保存的范围。

局限性

  • 证据主要基于病例报告和病例系列。
  • 需要更大样本、特征明确人群的进一步研究来确定最佳获取、冷冻保存和移植流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ovarian tissue cryopreservation involves freezing and storing of surgically retrieved ovarian tissue in liquid or vapour nitrogen below -190°C. The tissue can be thawed and transplanted back with the aim of restoring fertility or ovarian endocrine function. The techniques for human ovarian tissue freezing and transplantation have evolved over the last 20 years, particularly in the context of fertility preservation in pre-pubertal cancer patients. Fresh ovarian tissue transplantation, using an autograft or donor tissue, is a more recent development; it has the potential to preserve fertility and hormonal function in women who have their ovaries removed for benign gynaecological conditions. The techniques of ovarian tissue cryopreservation and transplantation have progressed rapidly since inception; however, the evidence on the success of this intervention is largely based on case reports and case series. OBJECTIVE AND RATIONALE: The aim of this study was to systematically review the current evidence by incorporating study-level and individual patient-level meta-analyses of women who received ovarian transplants, including frozen-thawed transplant, fresh or donor graft. SEARCH METHODS: The review protocol was registered with PROSPERO (CRD42018115233). A comprehensive literature search was performed using MEDLINE, EMBASE, CINAHL and Cochrane Central Register of Controlled Trials from database inception to October 2020. Authors were also contacted for individual patient data if relevant outcomes were not reported in the published manuscripts. Meta-analysis was performed using inverse-variance weighting to calculate summary estimates using a fixed-effects model. OUTCOMES: The review included 87 studies (735 women). Twenty studies reported on ≥5 cases of ovarian transplants and were included in the meta-analysis (568 women). Fertility outcomes included pregnancy, live birth and miscarriage rates, and endocrine outcomes included oestrogen, FSH and LH levels. The pooled rates were 37% (95% CI: 32-43%) for pregnancy, 28% (95% CI: 24-34%) for live birth and 37% (95% CI: 30-46%) for miscarriage following frozen ovarian tissue transplantation. Pooled mean for pre-transplant oestrogen was 101.6 pmol/l (95% CI: 47.9-155.3), which increased post-transplant to 522.4 pmol/l (95% CI: 315.4-729; mean difference: 228.24; 95% CI: 180.5-276). Pooled mean of pre-transplant FSH was 66.4 IU/l (95% CI: 52.8-84), which decreased post-transplant to 14.1 IU/l (95% CI: 10.9-17.3; mean difference 61.8; 95% CI: 57-66.6). The median time to return of FSH to a value <25 IU/l was 19 weeks (interquartile range: 15-26 weeks; range: 0.4-208 weeks). The median duration of graft function was 2.5 years (interquartile range: 1.4-3.4 years; range: 0.7-5 years). The analysis demonstrated that ovarian tissue cryopreservation and transplantation could restore reproductive and hormonal functions in women. Further studies with larger samples of well-characterized populations are required to define the optimal retrieval, cryopreservation and transplantation processes. WIDER IMPLICATIONS: Ovarian tissue cryopreservation and transplantation may not only be effective in restoring fertility but also the return of reproductive endocrine function. Although this technology was developed as a fertility preservation option, it may have the scope to be considered for endocrine function preservation.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Khattak H, Malhas R, Craciunas L, et al. Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis. Hum Reprod Update. 2022. PMID: 35199164. doi:10.1093/humupd/dmac003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。